What is Atomo Diagnostics?
Headquartered in Australia, Atomo Diagnostics specializes in the development and supply of unique, integrated rapid diagnostic test devices. The company distinguishes itself by simplifying the testing process, replacing complex, multi-component kits with all-in-one platforms that improve accuracy and ease of use for both healthcare professionals and patients. By focusing on the intersection of clinical precision and user-centric design, Atomo has established a robust market position within the global diagnostic industry, effectively bridging the gap between laboratory-grade results and point-of-care accessibility.
How much funding has Atomo Diagnostics raised?
Atomo Diagnostics has raised a total of $11.8M across 4 funding rounds:
Multiple Rounds
$10.8M
Debt
$1M
Debt (2016): $6M with participation from The Global Health Investment Fund
Grant (2016): $1.4M, investors not publicly disclosed
Private Equity (2016): $3.5M supported by Global Health Investment Fund
Debt (2017): $1M featuring Grand Challenges Canada
Key Investors in Atomo Diagnostics
The Global Health Investment Fund
A specialized impact investment firm focused on the healthcare sector, dedicated to funding innovative health products that yield both financial returns and significant global health improvements.
Grand Challenges Canada
An organization committed to supporting high-impact innovations in global health, maternal care, and mental health through evidence-based partnerships and strategic funding.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Atomo Diagnostics?
With the support of its recent major strategic investment, Atomo Diagnostics is well-positioned to scale its manufacturing capabilities and expand its footprint in key international markets. The company is expected to leverage this capital to enhance its product pipeline, focusing on the integration of new diagnostic markers and the optimization of its supply chain to meet rising global demand. As the healthcare sector continues to prioritize decentralized testing, Atomo's strategic roadmap emphasizes long-term sustainability and the continued deployment of its innovative diagnostic platforms to improve patient outcomes worldwide.
See full Atomo Diagnostics company page
